These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 25007363)

  • 1. Evidence for supplemental treatments in androgenetic alopecia.
    Famenini S; Goh C
    J Drugs Dermatol; 2014 Jul; 13(7):809-12. PubMed ID: 25007363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia.
    Dhurat R; Chitallia J; May TW; Jayaraaman AM; Madhukara J; Anandan S; Vaidya P; Klenk A
    Skin Pharmacol Physiol; 2017; 30(6):298-305. PubMed ID: 29055953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural products for male androgenetic alopecia.
    Gupta AK; Talukder M; Bamimore MA
    Dermatol Ther; 2022 Apr; 35(4):e15323. PubMed ID: 35044013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution.
    Marotta JC; Patel G; Carvalho M; Blakeney S
    Int J Pharm Compd; 2020; 24(1):69-76. PubMed ID: 32023218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.
    Gassmueller J; Hoffmann R; Webster A
    Br J Dermatol; 2008 Jan; 158(1):109-15. PubMed ID: 17986309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hair restoration approaches for early onset male androgenetic alopecia.
    Bhatti HA; Basra MK; Patel GK
    J Cosmet Dermatol; 2013 Sep; 12(3):223-31. PubMed ID: 23992164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.
    Arca E; Açikgöz G; Taştan HB; Köse O; Kurumlu Z
    Dermatology; 2004; 209(2):117-25. PubMed ID: 15316165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of the treatment plan for androgenetic alopecia].
    Tsiskarishvili NV; Tsiskarishvili TsI
    Georgian Med News; 2007 Apr; (145):62-6. PubMed ID: 17525504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of hormonal therapy for female pattern (androgenic) alopecia.
    Scheinfeld N
    Dermatol Online J; 2008 Mar; 14(3):1. PubMed ID: 18627703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine and Its Pharmacological Benefits in the Management of Androgenetic Alopecia: A Review.
    Völker JM; Koch N; Becker M; Klenk A
    Skin Pharmacol Physiol; 2020; 33(3):93-109. PubMed ID: 32599587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical minoxidil: review of efficacy and safety.
    Katz HI
    Cutis; 1989 Jan; 43(1):94-8. PubMed ID: 2644080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
    Olsen EA; Whiting D; Bergfeld W; Miller J; Hordinsky M; Wanser R; Zhang P; Kohut B
    J Am Acad Dermatol; 2007 Nov; 57(5):767-74. PubMed ID: 17761356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgenetic alopecia and current methods of treatment.
    Bienová M; Kucerová R; Fiurásková M; Hajdúch M; Koláŕ Z
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Mar; 14(1):5-8. PubMed ID: 15818439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies.
    Whiting DA
    Eur J Dermatol; 2001; 11(4):332-4. PubMed ID: 11399540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study].
    Piraccini B; Starace M; Alessandrini A; Guarrera M; Fiorucci MC; Lorenzi S
    G Ital Dermatol Venereol; 2011 Dec; 146(6 Suppl 1):1-8. PubMed ID: 22189834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women.
    Tsuboi R; Tanaka T; Nishikawa T; Ueki R; Yamada H; Katsuoka K; Ogawa H; Takeda K
    Eur J Dermatol; 2007; 17(1):37-44. PubMed ID: 17324826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.
    Blume-Peytavi U; Hillmann K; Dietz E; Canfield D; Garcia Bartels N
    J Am Acad Dermatol; 2011 Dec; 65(6):1126-1134.e2. PubMed ID: 21700360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current management of androgenetic alopecia in men.
    Wolff H; Kunte C
    Eur J Dermatol; 1999 Dec; 9(8):606-9. PubMed ID: 10586125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.
    Lucky AW; Piacquadio DJ; Ditre CM; Dunlap F; Kantor I; Pandya AG; Savin RC; Tharp MD
    J Am Acad Dermatol; 2004 Apr; 50(4):541-53. PubMed ID: 15034503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.